{"disease":{"id":"cerebral-adrenoleukodystrophy","name":"cerebral adrenoleukodystrophy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02171104","title":"MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":149,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT06224413","title":"A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Genetix Biotherapeutics Inc.","has_results":false},{"nct_id":"NCT03852498","title":"A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Genetix Biotherapeutics Inc.","has_results":true},{"nct_id":"NCT01896102","title":"A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Genetix Biotherapeutics Inc.","has_results":true},{"nct_id":"NCT04528706","title":"A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":13,"lead_sponsor_name":"Minoryx Therapeutics, S.L.","has_results":false},{"nct_id":"NCT06030648","title":"MT2022-01: MSCs for ALD","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":10,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT03367546","title":"Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}